Chordate Medical

“The higher valuations of both listed and unlisted peers indicate that the market sees significant potential in the migraine market. It seems that investors are willing to invest in early-stage companies, driven by the hope of high future returns. This insight reinforces our view that the migraine market is attractive and that companies like Chordate, which are active in this area, can have a significant potential upside”, says Kalqyl in the analysis.

Chordate signed an agreement with Kalqyl for report monitoring and commissioned analyses in October, 2023. A significant portion of the analysis and conclusions is based on a comprehensive examination by Kalqyl of both listed and unlisted peer companies, with the aim to obtain an overall picture of valuations, particularly within the field of neurostimulation and similar methods for the treatment and prevention of migraines:

“When we analyze Chordate in this context, the company appears to be undervalued in comparison to all companies in our peer group. This is remarkable, especially considering the scientific basis on which Chordate's technology rests, the extensive patent protection, as well as the progress being made in materializing proof of concept in several markets. We find no obvious explanation for this discrepancy in values. Rather, our observations suggest that Chordate may be undervalued relative to its peers.

Furthermore, the higher valuations of both listed and unlisted peers indicate that the market sees significant potential in the migraine market. It seems that investors are willing to invest in early-stage companies, driven by the hope of high future returns. This insight reinforces our view that the migraine market is attractive and that companies like Chordate, which are active in this area, can have a significant potential upside”, says Kalqyl in the analysis.

“Kalqyl adopts the perspective of a potential buyer, aligning closely with Chordate's strategy. Our ambition is for shareholders and stakeholders to have access to a relevant analysis of the company and the market potential that corresponds with the company's strategy”, says Anders Weilandt, Chordate CEO.

Read the full analysis from Kalqyl